Onconetix Inc (ONCO)

$1.53 +0.01 (0.66%)
Market Cap 997,000.00
Revenue (ttm) 820,000.00
Net Income (ttm) -14.03M
EPS (ttm) N/A
PE Ratio 0.02
Forward PE N/A
Profit Margin -1,710.98%
Debt to Equity Ratio 0.00
Volume 603,700
Avg Vol 1,639,466
Day's Range N/A - N/A
Shares Out 656,000.00
Stochastic %K 6%
Beta 3.63
Analysts Strong Buy
Price Target N/A

Company Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the Panc...

Industry: Biotechnology
Sector: Healthcare
Phone: 513 620 4101
Address:
201 East Fifth Street, Suite 1900, Cincinnati, United States
drweinerdog1
drweinerdog1 Apr. 6 at 11:55 PM
$ONCO just one 700 percent day would be nice
0 · Reply
SniperMaster00
SniperMaster00 Apr. 6 at 11:28 PM
$MIGI nice move! $ONCO next
0 · Reply
drweinerdog1
drweinerdog1 Apr. 6 at 9:16 PM
$ONCO I think a run is definitely coming
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Apr. 6 at 7:02 PM
$ONCO Those $1.40 adds gonna be delicious.... Fake 50% correct pumpers gone... Now we can take it up 👆
0 · Reply
Taylor575
Taylor575 Apr. 6 at 7:00 PM
$ONCO Bout to get spicy 🌶️!
0 · Reply
SniperMaster00
SniperMaster00 Apr. 6 at 6:53 PM
$ONCO get in while you can, this could move quick! $UGRO $ELAB
0 · Reply
Mg_1970
Mg_1970 Apr. 6 at 6:51 PM
$ONCO Still in 🤞💪
0 · Reply
KuruHabesha
KuruHabesha Apr. 6 at 6:49 PM
$ONCO Adding!
0 · Reply
Taylor575
Taylor575 Apr. 6 at 6:49 PM
$ONCO
0 · Reply
Virealize340
Virealize340 Apr. 6 at 6:15 PM
$ONCO still here just in case if u don't understand low float stocks maybe u shouldn't be investing
1 · Reply
Latest News on ONCO
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

Apr 2, 2026, 8:30 AM EDT - 4 days ago

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Mar 31, 2026, 8:30 AM EDT - 6 days ago

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Mar 25, 2026, 12:47 PM EDT - 12 days ago

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Mar 23, 2026, 8:30 AM EDT - 14 days ago

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Sep 26, 2025, 8:30 AM EDT - 6 months ago

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Sep 26, 2025, 8:15 AM EDT - 6 months ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Sep 22, 2025, 8:00 AM EDT - 7 months ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jul 16, 2025, 8:17 AM EDT - 9 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 16, 2025, 8:22 AM EDT - 10 months ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Jun 11, 2025, 11:30 AM EDT - 10 months ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 4:50 PM EDT - 11 months ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onco-Innovations Uplists to Cboe Canada

May 22, 2025, 10:00 AM EDT - 11 months ago

Onco-Innovations Uplists to Cboe Canada

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 24, 2025, 8:45 AM EDT - 1 year ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Dec 12, 2024, 5:00 PM EST - 1 year ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS VRNA GRDX

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 4:45 PM EDT - 1 year ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 1 year ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 27, 2024, 2:41 PM EDT - 1 year ago

Crude Oil Rises; Onconetix Shares Spike Higher

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024, 11:45 AM EDT - 1 year ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024, 6:00 AM EST - 2 years ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Dec 18, 2023, 7:00 AM EST - 2 years ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Issues Letter to Shareholders

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Issues Letter to Shareholders

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 28, 2023, 4:30 PM EDT - 2 years ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 3, 2023, 1:02 PM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 28, 2023, 7:55 AM EDT - 3 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 21, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Jun 14, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 12, 2023, 6:32 PM EDT - 3 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

May 10, 2023, 12:15 PM EDT - 3 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 26, 2023, 3:44 PM EDT - 3 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 20, 2023, 7:30 AM EDT - 3 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

drweinerdog1
drweinerdog1 Apr. 6 at 11:55 PM
$ONCO just one 700 percent day would be nice
0 · Reply
SniperMaster00
SniperMaster00 Apr. 6 at 11:28 PM
$MIGI nice move! $ONCO next
0 · Reply
drweinerdog1
drweinerdog1 Apr. 6 at 9:16 PM
$ONCO I think a run is definitely coming
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Apr. 6 at 7:02 PM
$ONCO Those $1.40 adds gonna be delicious.... Fake 50% correct pumpers gone... Now we can take it up 👆
0 · Reply
Taylor575
Taylor575 Apr. 6 at 7:00 PM
$ONCO Bout to get spicy 🌶️!
0 · Reply
SniperMaster00
SniperMaster00 Apr. 6 at 6:53 PM
$ONCO get in while you can, this could move quick! $UGRO $ELAB
0 · Reply
Mg_1970
Mg_1970 Apr. 6 at 6:51 PM
$ONCO Still in 🤞💪
0 · Reply
KuruHabesha
KuruHabesha Apr. 6 at 6:49 PM
$ONCO Adding!
0 · Reply
Taylor575
Taylor575 Apr. 6 at 6:49 PM
$ONCO
0 · Reply
Virealize340
Virealize340 Apr. 6 at 6:15 PM
$ONCO still here just in case if u don't understand low float stocks maybe u shouldn't be investing
1 · Reply
SniperMaster00
SniperMaster00 Apr. 6 at 6:11 PM
$ONCO red to green let’s go! Next $ELAB
0 · Reply
Taylor575
Taylor575 Apr. 6 at 6:09 PM
$ONCO Now can we see some action? 🤷🏼‍♂️
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 6 at 6:08 PM
$ONCO
0 · Reply
Stockquote01
Stockquote01 Apr. 6 at 6:04 PM
$ONCO With this : As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. ** HOW DO YOU EVALUATE THE VALUE OF THE CO AS OF TODAY ? NOW MC IS ONLY 1m....?
0 · Reply
drweinerdog1
drweinerdog1 Apr. 6 at 5:42 PM
$ONCO at least 1.4 is solid support it seems
0 · Reply
Taylor575
Taylor575 Apr. 6 at 4:29 PM
$ONCO No volume today.. good time to buy I guess.
0 · Reply
Erog24
Erog24 Apr. 6 at 2:57 PM
$ONCO I’ll be bag holding this for a while …. Fuqqq
0 · Reply
Rbartholomew
Rbartholomew Apr. 6 at 2:12 PM
$ONCO
0 · Reply
MrGMac
MrGMac Apr. 6 at 2:10 PM
$ONCO
0 · Reply
Sashko2018
Sashko2018 Apr. 6 at 2:08 PM
$ONCO
0 · Reply
Taylor575
Taylor575 Apr. 6 at 1:32 PM
$ONCO Let’s go!
0 · Reply
TATTED_KEN
TATTED_KEN Apr. 6 at 12:13 PM
$GMEX $ONCO let’s print 💴. Main focus GMEX, looking for $.80s. $AUUD adding under $4.5 (fresh RS 500k float)
0 · Reply